(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 2.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Ginkgo Bioworks Holdings's revenue in 2025 is $237,417,000.On average, 1 Wall Street analysts forecast DNA's revenue for 2025 to be $10,535,737,860, with the lowest DNA revenue forecast at $10,535,737,860, and the highest DNA revenue forecast at $10,535,737,860. On average, 1 Wall Street analysts forecast DNA's revenue for 2026 to be $11,355,184,138, with the lowest DNA revenue forecast at $11,355,184,138, and the highest DNA revenue forecast at $11,355,184,138.
In 2027, DNA is forecast to generate $15,668,866,409 in revenue, with the lowest revenue forecast at $15,668,866,409 and the highest revenue forecast at $15,668,866,409.